findmyKOL
Clinical trialNCT07605702Not, yet, recruitingObservational

The Canopy Cancer Collective Clinical Registry Protocol

SponsorCanopy Cancer Collective, LLCEnrollment100,000Colorectal CancerGI CancerGI CancersGastrointestinal NeoplasmsPDACPDAC - Pancreatic Ductal Adenocarcinoma+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The Canopy Cancer Collective Clinical Registry Protocol Non-Interventional Data and Sample Collection Registry Protocol Number of study sites 15 Study Design - Observational, registry Primary Objective To systematically collect and store comprehensive data on gastrointestinal cancer patients, encompassing both their past medical history and future clinical experiences, to address specific future research questions related to these malignancies, to establish and share best practices, and to support quality improvement initiatives focused on enhancing patient care and outcomes. Secondary Objective(s) 1. Leverage the collective to increase access to molecular profile and biomarker (ctDNA) matched clinical trials across the treatment trajectory. 2\. Use real world data and patient reported outcomes to improve patient care throughout the treatment trajectory. Research Procedure(s) Collection of clinical and outcome data and cataloging and facilitating access to physical biological specimens and their associated data for future research purposes. Drugs/Devices used on Study None Study Population Patients with diagnosis of gastrointestinal (GI) cancers who seek care at one of the canopy centers and/or their affiliates Sample Size Up to 30000 patients in the prospective component Up to 70000 subjects will be enrolled on the retrospective component Study Duration for Individual Participants Anticipated to be at least 1 year Study Specific Abbreviations AE: Adverse Event CEC: Clinical Events Committee CT: Computed Tomography iCCA: Intrahepatic cholangiocarcinoma MRI: Magnetic Resonance Imaging OS: Overall Survival PFS: Progression Free Survival

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uc San Diego Health

    San Diego, California, United States

  • Moffitt Cancer Center

    Tampa, Florida, United States

  • Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, United States

  • Northwell Health

    Lake Success, New York, United States

  • Mt. Sinai

    New York, New York, United States

  • Cleveland Clinic

    Cleveland, Ohio, United States

  • Ut Southwestern Medical Center

    Dallas, Texas, United States

  • Ut Health San Antonio

    San Antonio, Texas, United States

  • Fred Hutch

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 May 2026
Primary completion
31 May 2036
Completion
31 May 2038
Last update posted
26 May 2026
Registered enrollment
100,000
Registry id
NCT07605702

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.